Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
31-45 of 4090 results
Roche’s advanced bladder cancer drug Tecentriq fails in phase 3 trial
Roche’s phase III IMvigor211 study of Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer (mUC) whose disease progressed during or after treatment with a platinum-based chemotherapy (previously treated) has failed to meet its primary endpoint of overall survival (OS) compared to chemotherapy.
Contract Research & Services > Clinical Trials > News
Array, Merck to evaluate binimetinib-Keytruda combination for colorectal cancer
Array BioPharma and Merck have entered into a clinical trial collaboration agreement to investigate the safety and efficacy of the former’s MEK inhibitor, binimetinib, with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in metastatic colorectal cancer patients with microsatellite stable tumors (MSS CRC).
Contract Research & Services > Clinical Trials > News
Daiichi Sankyo initiates phase 3b study of Lixiana
Daiichi Sankyo announced the initiation of the ENVISAGE-TAVI AF study of Lixiana by enrolling the first patient in the trial.
Contract Research & Services > Clinical Trials > News
Myovant’s hormonal therapy relugolix succeeds in phase 2 trial
Myovant Sciences has reported positive results from a placebo-controlled Phase 2 dose-finding trial evaluating the ability of relugolix to decrease heavy menstrual bleeding in women with uterine fibroids which was conducted by Takeda Pharmaceutical in Japan.
Contract Research & Services > Clinical Trials > News
Relvar Ellipta improves asthma control in Salford Lung Study
GlaxoSmithKline and Innoviva said that their asthma drug Relvar Ellipta yielded positive results from the Salford Lung Study (SLS) in 4,233 asthma patients treated by their own general practitioner in everyday clinical practice.
Contract Research & Services > Clinical Trials > News
Laquinimod fails to meet primary endpoint in multiple sclerosis trial
Teva Pharmaceutical Industries and Active Biotech announced that CONCERTO trial for laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) failed to meet its primary endpoint.
Contract Research & Services > Clinical Trials > News
Aeterna Zentaris’ endometrial cancer drug fails in phase 3 study
By PBR Staff Writer
A phase 3 clinical study of Aeterna Zentaris' Zoptrex (zoptarelin doxorubicin) in women with locally advanced, recurrent or metastatic endometrial cancer failed to achieve its primary endpoint.
Contract Research & Services > Clinical Trials > News
AstraZeneca elects to return AZD9412 drug rights to Synairgen
By PBR Staff Writer
AstraZeneca has opted to return rights on drug AZD9412 (inhaled interferon beta) to Synairgen, which did not meet the pharma giant's predefined criteria for progression in a trial.
Contract Research & Services > Clinical Trials > News
Clinical trial technology firm Science 37 raises $29m funding
Science 37 has raised $29m in Series C funding, led by Glynn Capital Management with participation from GV, to bring clinical trials directly into patients’ homes.
Contract Research & Services > Clinical Trials > News
Pfizer's Zavicefta matches standard-of-care in treating hospital-acquired pneumonia in phase 3 study
Results from the phase 3 REPROVE study assessing Pfizer's fixed-dose antibacterial combo Zavicefta (ceftazidime-avibactam) in patients with hospital-acquired pneumonia (HAP) demonstrated a comparable cure rate to carbapenem antibiotic therapy, considered the standard of care.
Contract Research & Services > Clinical Trials > News
NGM Bio’s NGM282 succeeds in nonalcoholic steatohepatitis phase 2 trial
NGM Bio’s NGM282 has met the primary and key secondary endpoints in a Phase 2 trial in nonalcoholic steatohepatitis (NASH) patients.
Contract Research & Services > Clinical Trials > News
AbbVie's pan-genotypic HCV regimen achieves 99% cure rate in phase 3 study
By PBR Staff Writer
A phase 3 study demonstrated that AbbVie's pan-genotypic ribavirin-free HCV regimen of glecaprevir/pibrentasvir (G/P) achieved a 99% cure rate after 12 weeks of treatment.
Contract Research & Services > Clinical Trials > News
Ultragenyx's hypophosphatemia drug succeeds in phase 3 study
Ultragenyx Pharmaceutical, Kyowa Hakko Kirin and Kyowa Kirin International have reported positive 24-week data from the randomized, double-blind, placebo-controlled Phase 3 trial of burosumab (KRN23) in X-linked hypophosphatemia (XLH) adult patients.
Contract Research & Services > Clinical Trials > News
Relypsa’s Veltassa shows consistent efficacy in phase 4 trial to treat hyperkalemia
By PKBR Staff Writer
Relypsa’s Veltassa (patiromer) has demonstrated consistent effficacy and safety in phase 4 Tourmaline study in patients with hyperkalemia.
Contract Research & Services > Clinical Trials > News
Mateon’s phase 2/3 trial in platinum-resistant ovarian cancer yields positive results
Mateon Therapeutics has revealed encouraging data from its first interim scheduled analysis of the ongoing phase 2/3 trial (FOCUS) in platinum resistant ovarian cancer (prOC) patients.
Contract Research & Services > Clinical Trials > News
31-45 of 4090 results